Pipecilli is an oral cell cyclin-dependent kinases (CDKs) 4 and 6 inhibitor that specifically inhibits CDK4/6 protein kinases in cell cycle progression, thereby inhibiting the proliferation and growth of cancer cells.At the same time, perphenazine can enhance the efficacy of chemotherapeutic drugs and reduce the resistance of breast cancer cells to chemotherapy.The results of clinical trials show that the combination of Perpercillis capsules with hormone therapy can significantly prolong the survival of patients with advanced breast cancer.

The approved indication for perphentermine in the United States is for the treatment of locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, in combination with an aromatase inhibitor as initial endocrine therapy for postmenopausal female patients.